ZhongYin Assists CNPIC in Successful Issuance of Bonds
Recently, China National Pharmaceutical Investment Co., Ltd. (“CNPIC”) has successfully issued 2022 Corporate Bonds Publicly-offered to Professional Investors (Tranche 1) (referred to as "22 CNPIC 01"). 22 CNPIC 01 is underwritten by China Securities Co., Ltd. and is publicly offered to professional investors. This tranche is the first one, which is issued to raise RMB 700 million yuan, with a term of 2+1 years and a coupon rate of 2.78%.
The issuer, China National Pharmaceutical Investment Co., Ltd., is a company wholly-owned by China National Pharmaceutical Group Corporation and actually controlled by the State Council, and has a registered capital of RMB 3 billion yuan and an AUM of over RMB 20 billion yuan. With the strategic positioning of “based on the industry, service the group, and be a professional investment and financing company in the medicine and big health industry”, the issuer provides financial facility, equity investment, and other financial services in the fields closely related to the medicine and big health industry, and has established a development model of industry-finance integration with the characteristics of Sinopharm. It focuses on industrial merger and acquisition and industrial chain integration, and technology innovation and model innovation, and gives full play to its synergy effect with various industrial sectors within the group, in order to realize business linkage, resource sharing, and promote the group's leapfrog development.
As entrusted by the issuer, the team led by LI Zheng of ZhongYin Law Firm has provided comprehensive legal services for the registration and issuance of 22 CNPIC 01. With its professional, efficient, diligent, and experienced legal services, the team has been highly recognized by the issuer and related intermediaries. LI Zheng's team mainly practices in areas such as comprehensive corporate affairs, securities and capital markets, litigation and arbitration, and bankruptcy and restructuring, and has outstanding expertise and extensive practical experience in these areas.
It was the first one
It was the last one